mecamylamine
Trade name: inversine
Small moleculeapproved
Approved
Mar 1, 1956
Mecamylamine is a non-selective, non-competitive antagonist of the nicotinic acetylcholine receptors (nAChRs) that was introduced in the 1950s as an antihypertensive drug. In the United States, it was voluntarily withdrawn from the market in 2009 but was brought to market in 2013 as Vecamyl and eventually was marketed by Turing Pharmaceuticals. — Wikipedia
Clinical trial activity
19 trials · 18 clinical orgs · 4 marketing orgs
Phase 1
7
Phase 2
9
Phase 3
1
Phase 4
1
Earliest trial started Jan 1, 1997 (NCT00018161)
Timeline
1950s
2000s
- Jan 1, 2007
Earliest Phase 3 Sponsor(trial)
2010s
- Mar 19, 2013
LGM Pharma — Marketing Organization
- Mar 19, 2013
Nexgen Pharma, Inc — Marketing Organization
Indications
Approved for
Studied for
- Aging · Early Phase 1
- Alcoholism · Phase 3
- Alzheimer Disease · Early Phase 1
- Autistic Disorder · Phase 1
- Cognition Disorders · Early Phase 1
- Depression · Phase 3
- Depressive Disorder · Phase 2
- Growth and Development · Phase 1
- Healthy Aging · Phase 1
- Macular Degeneration · Phase 2
- Macular Edema · Phase 2
- Major Depressive Disorder · Phase 2
- Orthostatic Intolerance · Phase 1/Phase 2
- Postmenopause · Early Phase 1
- Smoking · Phase 2
- Spinal Cord Injuries · Phase 4
- Tachycardia · Phase 1/Phase 2
Mechanism of action
- Neuronal acetylcholine receptor; alpha3/beta4NEGATIVE ALLOSTERIC MODULATOR
Neuronal acetylcholine receptor; alpha3/beta4 negative allosteric modulator
Approval history
- approvedPriority reviewMar 1, 1956
Chemistry & pharmacology
Loading structure…
SMILES
CNC1(C)C2CCC(C2)C1(C)C- Mol. weight
- 167.3 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL267936 ↗
- WikipediaMecamylamine ↗
- ChEMBLCHEMBL263807 ↗
- ChEMBLCHEMBL1398031 ↗
- ChEMBLCHEMBL1237082 ↗
- ChEMBLCHEMBL1182743 ↗
Also known as
- inversine
- inversine
- inversine
- mecamine
- mecamylamine
- mecamylamine
- mecamylamine
- mecamylamine
- mecamylamine
- mecamylamine
- mecamylamine
- mecamylamine
- mecamylamine
- mecamylamine
- mecamylamine
- mecamylamine chloride
- mecamylamine chloride
- mecamylamine hcl
- mecamylamine hcl
- mecamylamine hcl
- mecamylamine hydrochloride
- mecamylamine hydrochloride
- mecamylamine hydrochloride
- mecamylamine hydrochloride
- revertina
- versamine
- versamine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06002477 | Early Phase 1 (Phase 1) | Mar 1, 2024 | Vanderbilt University |
| NCT05538910 | N/A | Dec 29, 2022 | National Institute on Drug Abuse (NIDA) |
| NCT04756232 | Early Phase 1 (Phase 1) | Oct 1, 2021 | Vanderbilt University |
| NCT04129060 | Early Phase 1 (Phase 1) | Nov 30, 2019 | University of Vermont, Vanderbilt University |
| NCT03914677 | Phase 4 | Apr 18, 2019 | Wayne State University |
| NCT03408574 | Phase 1 | Oct 1, 2016 | University of Vermont, Vanderbilt University |
| NCT01223404 | N/A | Oct 1, 2010 | National Institute on Drug Abuse (NIDA), University of Maryland |
| NCT00607750 | Phase 2 | May 1, 2008 | CoMentis |
| NCT00536692 | Phase 2 | Sep 1, 2007 | CoMentis, Juvenile Diabetes Research Foundation |
| NCT00563797 | Phase 3 | Aug 1, 2007 | Brain & Behavior Research Foundation, Yale University |
| NCT00773812 | Phase 1 | Jul 1, 2007 | Autism Speaks, Ohio State University |
| NCT00455650 | N/A | Mar 1, 2007 | Brain & Behavior Research Foundation, Harvard University, The Bowman Family Foundation |
| NCT00414206 | Phase 2 | Mar 1, 2007 | CoMentis |
| NCT00593879 | Phase 2 | Feb 1, 2005 | Targacept |
| NCT00342563 | Phase 2 | May 1, 2004 | Yale University |
| NCT00319319 | Phase 2 | Jan 1, 2003 | Donaghue Foundation, Yale University |
| NCT00018187 | Phase 1 | Nov 1, 1998 | Department of Veteran Affairs |
| NCT00262470 | Phase 1/Phase 2 (Phase 2) | Apr 1, 1997 | National Institutes of Health (NIH), University of Calgary, Vanderbilt University |
| NCT00018161 | Phase 2 | Jan 1, 1997 | Department of Veteran Affairs |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vanderbilt University | Academic/Hospital | 5 | 2 | 2 | 1997 |
| CoMentis | For profit | 3 | 3 | 1 | 2007 |
| Yale University | Academic/Hospital | 3 | 3 | 2 | 2003 |
| Brain & Behavior Research Foundation | Academic/Hospital | 2 | 0 | 2 | 2007 |
| Department of Veteran Affairs | Government | 2 | 2 | 2 | 1997 |
| National Institute on Drug Abuse (NIDA) | Government | 2 | 1 | 1 | 2010 |
| University of Vermont | Academic/Hospital | 2 | 2 | 1 | 2016 |
| Autism Speaks | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Donaghue Foundation | Academic/Hospital | 1 | 0 | 1 | 2003 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Juvenile Diabetes Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2007 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 1997 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Targacept | For profit | 1 | 1 | 1 | 2005 |
| The Bowman Family Foundation | Academic/Hospital | 1 | 0 | 1 | 2007 |
| University of Calgary | Academic/Hospital | 1 | 1 | 1 | 1997 |
| University of Maryland | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Wayne State University | Academic/Hospital | 1 | 1 | 1 | 2019 |
18 organizations
Page 1 / 1
Marketing (4)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| LGM Pharma | For profit | MKTG | Mar 19, 2013 |
| Merck | For profit | NDA | Mar 1, 1956 |
| Nexgen Pharma, Inc | For profit | MKTG | Mar 19, 2013 |
| Targacept | For profit | NDA2 | Mar 1, 1956 |